Abstract View

Author(s): Choddabattina Rajkumar*11, Thuribhatla Rohith12, Dr Thripuramallu J Mohanrao23

Email(s): 1chrajesh2050@gmail.com

Address: Address Not Available

Published In:   Volume - 5,      Issue - 9,     Year - 2026

DOI: https://doi.org/10.71431/IJRPAS.2026.5908  

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Neurodegenerative disorder Alzheimer’s disease (AD) is a progressive condition characterized by cognitive issues, functionality problems of neurons, and the accumulation of neurofibrillary tangles and amyloid-beta plaques. Despite progress in therapy development, effective treatment of the disease is difficult due to the existence of the blood-brain barrier (BBB), which prevent many therapeutic agents from entering the brain. The emergence of drug delivery systems based on nanotechnology is seen as a possible way of overcoming this problem, enabling the increase of drug stability, bioavailability, targeted delivery, and controlled release in the central nervous system. Researchers investigated a number of nanocarriers, such as polymeric nanoparticles, lipid nanoparticles, dendrimers, liposomes, solid lipid nanoparticles, and nanogels for BBB targeting. Various ligands are used for the surface modification of nanoparticles; for example, transferrin, peptides, antibodies, lactoferrin and lipoproteins, which makes it possible for them to undergo receptor-mediated transcytosis, hence improving the delivery of the drugs to the brain. Novel approaches utilizing multifunctional nanocarrier systems, mimic nanoparticles, intranasal administration as well as systems responsive to specific stimuli provide more opportunities to optimize the therapeutic effect of drugs. Nevertheless, it still remains problematic to address toxicity, safety, biodegradability, manufacturing and efficacy of clinical use. Thus, further studies are necessary to create safe, efficient and clinically relevant nanotechnology solutions for treatment of Alzheimer’s disease.

Cite this article:
Choddabattina Rajkumar, Thuribhatla Rohith, Dr Thripuramallu J Mohanrao. Nanotechnology-Based Drug Delivery Systems for Alzheimer’s Disease: Emerging Strategies for Blood–Brain Barrier Targeting. IJRPAS, September 2026; 5(9): 127-146.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2026.5908


References not available.

Related Images:



Recent Images



Methyl Red in Materials Engineering: A Systematic Review of Physicochemical, Energetic and Technological Applications Using the PRISMA Methodology
Nature to Laboratory Translation of Indole Scaffolds: Integrating Natural Product Diversity, Sustainable Synthesis, and Evidence Guided Medicinal Chemistry
Antidiuretic Hormone Deficiency and Central Diabetes Insipidus (Arginine Vasopressin Deficiency): Pathophysiology, Etiology, and Contemporary Management Strategies
Mechanistic Evaluation of Acalypha hispida in Psoriasis Using Network Pharmacology and In-vivo Experimental Models
Formulation and Evaluation of Solubility enhanced Aripiprazole Oro Dispersible Film for the improved patient compliance
LipoEdge™ Liposomal Zinc by WBCIL: From Critical Quality Attributes to Bioavailability Validation and Formulation Applications
Network Pharmacology: A Systems Biology Approach to Drug Discovery and Disease Mechanisms
Artificial Intelligence in Pharmaceutical Formulation Development: From Trial-and-Error to Data-Driven Design
Evaluation of In-Vitro Anti-Diabetic Activity And   Antioxidant Activity In Ethanolic and Hydroalcoholic Extract of leaves of Gymnema Sylvestre
Molecular Docking Approaches in Antibacterial Drug Discovery: Computational Insights into Natural Compounds

Tags